ACADIA Pharmaceuticals (ACAD) has been under a strong bear grip, hence the stock is down -8.31% when compared to the S&P 500 in the past 4 weeks. However, in the near-term, buying emerged at lower levels and the stock has outperformed the S&P 500 by 7.27% in the past 1 week. The stock has risen by 7.24% in the past week indicating that the buyers are active at lower levels, but the stock is down -7.96% in the past 4 weeks.
ACADIA Pharmaceuticals Inc. has dropped 1.18% during the last 3-month period . Year-to-Date the stock performance stands at -5.64%. The stock has recorded a 20-day Moving Average of 3.71% and the 50-Day Moving Average is 3.33%.
ACADIA Pharmaceuticals (NASDAQ:ACAD): During Fridays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $33.14 and $33.03 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $33.90. The buying momentum continued till the end and the stock did not give up its gains. It closed at $33.64, notching a gain of 1.11% for the day. The total traded volume was 1,349,269 . The stock had closed at $33.27 on the previous day.
Also, Equity Analysts at the Brokerage Firm, Bank of America, downgrades their rating on the shares of ACADIA Pharmaceuticals (NASDAQ:ACAD). Bank of America has a Neutral rating on the shares. Previously, the analysts had a Buy rating on the shares. The rating by the firm was issued on June 22, 2016.
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for the treatment of neurological and related central nervous system disorders. The Companys drug candidate NUPLAZID (pimavanserin) is under development for the treatment of Parkinsons disease psychosis, Alzheimers disease psychosis, Schizophrenia and Sleep disturbances. The Company is also conducting preclinical programs for alpha adrenergic agonists indicated for the treatment of chronic pain and muscarinic drugs for the treatment of glaucoma. NUPLAZID has an active ingredient pimavanserin, is a selective serotonin inverse agonist (SSIA) preferentially targeting 5-HT2A receptors that was discovered by the Company. The Company in collaboration with Allergan, has discovered and engaged in the development of small-molecule product candidates, such as alpha adrenergic agonists and muscarinic receptors.